Skip to main content

This site is intended for US healthcare professionals only.

NOW
APPROVED

Phexxi is an innovative, non-hormonal, first-in-class vaginal pH regulator (VPR)—a bioadhesive gel used in the moment to maintain the natural pH of the vagina to prevent pregnancy.1

READ THE PRESS RELEASE HERE  >

AVAILABLE IN PHARMACIES SOON!

Phexxi will be available for prescription in the United States in September. For updates on the availability of Phexxi, and for more information, please sign up below or contact Evofem Biosciences at evofem.com.

STAY INFORMED

Please select:
Form Submitted Thank You

FOR YOUR PATIENTS WHO ARE
BEYOND HORMONES

large script pink pHinally graphic with upper case h
THERE'S PHEXXI

Your patients may be characterized as beyond hormones if they:

  • Cannot use hormonal contraception due to comorbidities or other risk factors
  • Have concerns about exposure to hormonal contraception
  • Are embracing a natural lifestyle across all aspects of their lives
  • Have had side effects from hormonal birth control
  • Have given up on available birth control methods
  • Are currently using hormonal birth control, but don’t find it to be the best option for their bodies and lives

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females of reproductive potential with history of recurrent urinary tract infection or urinary tract abnormalities.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection, urinary tract infection, vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain.

Patients should be counseled on the following:

  • To contact and consult their healthcare provider for severe or prolonged genital irritation or experiencing urinary tract symptoms.
  • To discontinue Phexxi if they develop a local hypersensitivity reaction.
  • That Phexxi does not protect against HIV infection or other sexually transmitted infections.

Please see full Prescribing Information for Phexxi.

To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or you may contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

REFERENCE:

1. Bayer LL, Jensen JT. ACIDFORM: a review of evidence. Contraception. 2014;90:11-18.

Expand ISI

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.